Advances in the study of CD47‐based bispecific antibody in cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Immunology"
DOI: 10.1111/imm.13498
Abstract: Tumour therapy has entered the era of immunotherapy. Monoclonal antibodies (mAb), immune checkpoint inhibitors, chimeric antigen receptor T‐cell (CAR‐T), cytokine‐induced killer (CIK), tumour‐infiltrating lymphocytes (TILs) and other cellular immunotherapies have become the focus of current… read more here.
Keywords: immunotherapy; cd47 based; cd47 sirp; based bispecific ... See more keywords
Abstract 3184: Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-3184
Abstract: Background: Tumor immunotherapy, especially the combination of PD-1/PD-L1 inhibitors and chemotherapy, has developed rapidly. However, the systemic side effects induced by chemotherapy remain a crucial problem that needs to be addressed. Antibody-drug conjugates (ADCs) are… read more here.
Keywords: cancer; mmae; cpl976 mmae; based bispecific ... See more keywords